Role of autologous and allogeneic stem cell transplantation in myeloma

  title={Role of autologous and allogeneic stem cell transplantation in myeloma},
  author={William Ira Bensinger},
The treatment of multiple myeloma (MM), a largely incurable B-cell hematologic malignancy, is changing dramatically. Autologous stem cell transplantation (SCT) and the approval of two new classes of drugs, immunomodulators and proteosome inhibitors, have resulted in improved response rates and increased overall survivals. Thalidomide, bortezomib and lenalidomide have been combined with corticosteroids, alkylators and anthracyclines in front-line MM treatment. Phase 2 and preliminary phase 3… CONTINUE READING
24 Citations
69 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 24 extracted citations


Publications referenced by this paper.
Showing 1-10 of 69 references

Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/ 01 trial

  • JL Harousseau, C Mathiot, M Attal, G Marit, D Caillot, T Hullin
  • J Clin Oncol
  • 2008

Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial

  • M Macro, M Divine, Y Uzunhan, A Jaccard, D Bouscary, V Leblond
  • Blood
  • 2008

A phase II trial of autologous stem cell transplant (AHSCT) followed by mini-allogeneic stem cell transplant (AlloTx) for the treatment of multiple myeloma: analysis of ECOG E4A98

  • DH Vesole, L Zhang, N Flomenberg, PR Greipp, HM. Lazarus
  • Blood
  • 2007

Similar Papers

Loading similar papers…